Evaluation of Ecallantide for Treatment of Angiotensin Converting Enzyme (ACE) Inhibitor Induced Angioedema

PHASE2

Phase

TERMINATED

Status

Enrollment

INDUSTRY

Sponsor class

Stopped Interim analysis suggested a trend favoring ecallantide; observed response rate to placebo was substantially higher than described in medical literature.

Conditions

ACE Inhibitor Induced Angioedema

Interventions

DRUG: ecallantide 60 mg
DRUG: ecallantide 30 mg
DRUG: ecallantide 10 mg
DRUG: placebo
DRUG: placebo match for 30 mg ecallantide arm
DRUG: placebo match for 10 mg ecallantide arm

Sponsor

Shire